Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alphaDC1-TBVA Vaccine + Gemcitabine in Metastatic Breast Cancer
NCT02479230Phase 1Completed
- Start
- Jul 2015
- Primary completion
- Oct 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous alpha-DC1/TBVA vaccine in breast cancer. Primary endpoint: Number of toxicities. Started Jul 2015; status: completed.
02
Drugs
autologous alpha-DC1/TBVA vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02479230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02479230.